Abstract: The present invention provides a method of producing a cell sheet including the following steps (1) seeding and culturing retinal pigment epithelial cells on a collagen gel to form a cell sheet composed of the retinal pigment epithelial cells, and (2) degrading the collagen gel with collagenase to detach the cell sheet composed of the retinal pigment epithelial cells, and the like.

Abstract: A medium which comprises a fibroblast growth factor (FGF), and a sulfated compound or a pharmaceutically acceptable salt thereof at a concentration which promotes the growth of a stem cell in the presence of FGF, is useful for culturing stem cells.

Abstract: The invention relates to implantable collagen devices made by seeding at least one elongate collagen construct, e.g., comprising at least one elongate synthetic collagen fiber with a plurality of cells and applying a strain and/or stress to the at least one elongate collagen fiber to induce the cells to differentiate into target phenotypes, e.g., tendon or ligament phenotype cells (and/or fibroblasts), typically with an extracellular matrix of collagen to organize into a tissue on the at least one collagen fiber.

Abstract: Disclosed is a method for preserving an organ in a donation after brain death donor or a donation after cardiac death donor comprising administering to the donor a composition comprising at least one globin, one globin protomer or one extracellular hemoglobin of Annelida, a stabilizing solution and/or a solution for conserving organs, said composition having a temperature of between 0° C. and 37° C. Also disclosed is a method for conserving an organ in situ in a donation after brain death donor or a donation after cardiac death donor using normothermic ECMO or double-balloon triple-lumen catheter techniques or any other similar technique.

Abstract: One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day.

Abstract: Disclosed herein is an industrial scale process of cultivating cultivating Ganoderma lucidum mycelia. As high as 15 Kg dried Ganoderma lucidum mycelia may be produced from about 300 liters liquid culture every 30 days, and the resulting dried Ganoderma lucidum mycelia are rich in triterpenoids that include at least ganoderic acid S (GAS), ganoderic acid T (GAT), ganoderic acid Me (GAMe), ganoderic acid R (GAR), and ganodermic acid S (GMAS).

Abstract: The subject matter of the invention is a functional population of human brown adipocytes, in which the expression of UCP1, CIDEA, CPT1B and Bc12 is higher, the expression of Bax is lower and the expression of PPAR-alpha, PGC-1alpha, PGC-1 beta and PRDM16 is similar compared with the corresponding expressions of a population of human white adipocytes. The invention also relates to a method for differentiation of hMADS cells into the functional population of human brown adipocytes, to a method for conversion of a population of human white adipocytes into the functional population of human brown adipocytes, and also to a method of screening for molecules capable of modulating the bodyweight in an individual.

Abstract: One aspect of the present disclosure can include a therapeutic composition useful for treatment of a genitourinary disorder. The composition can be derived from a culture media having been in contact with a population of bone marrow-derived mesenchymal stem cells for a sufficient time period necessary to endow therapeutic activity in the culture media. The therapeutic property endowed to the culture media is the ability to promote structural and functional recovery of a dysfunctional organ or biological tissue associated with the genitourinary disorder.

Abstract: A method for producing an implant material by: (A): setting a porous ceramic material having substantially unidirectionally arrayed pores at any depth position inside a container, (B): filling the container with a cell-containing liquid containing at least bone marrow blood and/or peripheral blood, and (C): applying, on the container, a centrifugal force in the direction along the axis of the container.

Abstract: The invention provides methods and systems for the production of lipid products from a gaseous substrate using a two stage fermentation process. The method comprises providing a gaseous substrate comprising CO, CO2 and H2 or mixtures thereof, to a first bioreactor containing a culture or one or more microorganisms, and fermenting the substrate to produce a product comprising acetate. The acetate from the first bioreactor is then provided to a second bioreactor, where it is used as a substrate for fermentation to lipids by one or more yeasts.

Abstract: A somatic stem cell that is CD10+, CXCR4+, and CD31+ and another somatic stem cell that is CD105+, CD44+, and nestin+. Also disclosed are both a method of preparing these stem cells and a method of using them to treat degenerative diseases, e.g., a muscle-degenerative disease. The invention further includes making and using liver cells derived from the somatic cell that is CD105+, CD44+, and nestin+.

Abstract: The present invention relates to a method for treating a lignocellulose biomass in order to dissolve the lignin therein, while the cellulose does not dissolve. The cellulose pulp obtained can be used to produce glucose. In addition the lignin can be isolated for subsequent use in the renewable chemical industry as a source for aromatic platform chemicals.

Abstract: Biomaterial having a multi-dimensional structure and comprising demineralized bone matrix dispersed within differentiated mesenchymal stem cells (MSCs) tissue, wherein MSCs are adipose tissue-derived stem cells. Method for producing this biomaterial comprising incubating MSCS in osteoblastic and/or chondrongenic medium in presence of demineralized bone matrix. Use of this biomaterial for alleviating or treating a bone or cartilage defect, supporting or correcting a congenital or acquired abnormality, supporting a bon or articular bone replacement following surgery or trauma, and/or supporting a musculoskeletal implant.

Abstract: The present invention provides a method for determining whether or not a test sample contains a phytopathogenic oomycete selectively from two kinds of oomycetes of a phytopathogenic oomycete and a non-phytopathogenic oomycete. The method according to the present invention comprises: (a) putting the test sample on a front surface of a cellulose film; wherein the cellulose film has a thickness of not less than 0.5 micrometers and not more than 3.7 micrometers; (b) leaving the test sample at rest for not less than 4 hours and not more than 8 hours after the step (a); (c) observing a back surface of the film after the step (b); and (d) determining that the test sample contains the phytopathogenic oomycete, if an oomycete is found on the back surface of the film in the step (c).

Abstract: The present invention provides a method for determining whether or not a test sample contains a phytopathogenic oomycete selectively from two kinds of oomycetes of a phytopathogenic oomycete and a non-phytopathogenic oomycete. The method according to the present invention comprises: (a) putting the test sample on a front surface of a cellulose film; wherein the cellulose film has a thickness of not less than 0.5 micrometers and not more than 3.7 micrometers; (b) leaving the test sample at rest for more than 8 hours and not more than 12 hours after the step (a); (c) observing a back surface of the film after the step (b); and (d) determining that the test sample contains the phytopathogenic oomycete, if an oomycete is found on the back surface of the film in the step (c).

Abstract: The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic ?-cell.

Abstract: A method of producing a sugar liquid from cellulose-containing biomass includes (1) to (4): (1) subjecting a cellulose-containing biomass to a dilute sulfuric acid treatment and thereafter separating the treated cellulose-containing biomass into a dilute sulfuric acid-treated liquid and a cellulose-containing solid content; (2) adding a cellulase to the cellulose-containing solid content to hydrolyze the cellulose and thereafter obtaining a sugar liquid; (3) filtering the dilute sulfuric acid-treated liquid through a nanofiltration membrane at pH 2.5 or lower to thereby separate a sugar concentrated liquid as a retentate and at the same time recover a sulfuric acid aqueous solution as a permeate; and (4) reusing the whole amount or a part of the sulfuric acid aqueous solution obtained in (3) in the dilute sulfuric acid treatment in (1).

Abstract: The present invention relates to a separation system and a separation material for easily and rapidly separating a red blood cell-rich fraction, a white blood cell-rich fraction, and/or a platelet-rich fraction from a biological fluid containing these blood cell components without the necessity of performing centrifugation. The separation of a red blood cell-rich fraction, a white blood cell-rich fraction, and/or a platelet-rich fraction from a biological fluid can be accomplished by capturing white blood cells and platelets on a blood cell separation material by contacting the biological fluid with the blood cell separation material, thereby providing a red blood cell-rich fraction; and recovering a white blood cell-rich fraction by separating white blood cells captured from the resulting blood cell separation material using a separation solution.

Abstract: A method of processing liquid biological material includes providing a liquid processing system. The liquid processing system includes a trunk, a first arm, a second arm, a driving mechanism, and physiochemical equipment. The first arm includes a first robot hand. The second arm includes a second robot hand. A process is performed on a cell suspension in which periphytic cultured cells are suspended as a liquid biological material. In the process, a culture vessel is held with the first robot hand in a state with an open top of the culture vessel facing upwards. The culture vessel has a culture face where the cultured cells are cultured on a base thereof. A cell scraper is held with the second robot hand. The cell scraper is provided with a blade to scrape the cultured cells from the culture face.

Abstract: A method for manufacturing a multilayered cell sheet characterized in fabricating a vascular bed that constructs a vascular network extending to the surface from a channel for perfusing a medium, the channel being embedded in a gel; and layering a cell sheet onto the vascular bed to construct a vascular network in the cell sheet. This manufacturing method makes it possible to construct a vascular network in the cell sheet and to fabricate a thick multilayered cell sheet in a simple manner by layering cell sheets. Such a thick multilayered cell sheet is useful as an in-vivo tissue substitute in regenerative medicine involving a variety of tissues.